iCRYO Adds Dr. Jason Sonners to Medical Advisory Board, Strengthens Commitment to Safe, Effective Hyperbaric Oxygen Therapy
Dr. Sonners is the author of Oxygen Under Pressure and The Art and Science of Hyperbaric Medicine, which capture his extensive research and knowledge of application of HBOT. His expertise in integrative healthcare, particularly in neurodegenerative diseases, trauma recovery, and longevity medicine, aligns seamlessly with iCRYO's mission to elevate people's quality of life through affordable, professional, and convenient personal health services.
As a certified hyperbaric practitioner and Clinic Director of NJ HBOT and HBOT USA, Dr. Sonners has transformed patient outcomes through innovative protocols combining HBOT with nutrition, exercise, and other therapies and modalities.
"Dr. Sonners' unparalleled expertise in hyperbaric oxygen therapy and his holistic approach to wellness make him an invaluable addition to our Medical Advisory Board," said Kyle Jones, CEO and Co-founder of iCRYO. "His leadership in advancing HBOT research and safe practices will enhance our ability to deliver transformative health solutions within the iCRYO ecosystem, ensuring our guests achieve optimal results while prioritizing safety."
iCRYO remains dedicated to offering HBOT in the safest, most effective manner possible. HBOT, which for iCRYO guests involves pressurized ambient air, not pure supplemented oxygen, in an enclosed chamber, promotes tissue repair, reduces inflammation, and accelerates healing.
With Dr. Sonners' guidance, iCRYO will implement rigorous safety protocols and evidence-based practices to maximize the therapy's benefits while minimizing risks. His expertise ensures every guest receives personalized, high-quality care tailored to their unique needs, reinforcing iCRYO's position as an industry leader in wellness innovation.
"I'm honored to bring my years of research and experience to iCRYO's Medical Advisory Board," said Dr. Sonners. "iCRYO has assembled a world class suite of services and a world class team of medical professionals to guide its practices into the future. I am excited to work more closely with them to make the amazing benefits of hyperbaric oxygen therapy more readily accessible to more people."
This strategic addition underscores iCRYO's commitment to integrating advanced therapies with a focus on safety and efficacy, empowering guests to achieve peak health and longevity.
About iCRYO
Founded in 2015, iCRYO's mission is to elevate the quality of life of its team members, guests, and franchisees by providing affordable, professional, and convenient personal health services while raising the standard as a global wellness brand. To learn more about its services, locations, and franchise opportunities, visit www.icryo.com.
iCRYO Media Contact
Robbie JenkinsDirector of Communicationsrobbie.jenkins@icryo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/icryo-adds-dr-jason-sonners-to-medical-advisory-board-strengthens-commitment-to-safe-effective-hyperbaric-oxygen-therapy-302515061.html
SOURCE iCRYO
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
7 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Axios
7 hours ago
- Axios
Houston Methodist Hospital named best hospital in Texas by U.S. News
Houston Methodist Hospital continues to rank as the best hospital in Texas, and several other Houston-area hospitals also topped the state rankings, according to U.S. News & World Report's annual analysis, published Tuesday. Why it matters: Houston's world-class medical care means good health care access for locals — plus it draws people to the city as a place to live, work and seek treatment. State of play: U.S. News' ranking compared more than 4,400 hospitals by patient outcomes across 20 benchmark procedures like knee replacement and heart bypass surgery, as well as other data sources like Medicare and patient surveys. Zoom in: For the 14th year, Houston Methodist was named the top hospital in Texas. It also landed a spot on the national Best Hospitals Honor Roll again. Six Houston-area hospitals made the state's top 10 list, including Baylor St. Luke's Medical Center, Memorial Hermann Hospital and its Greater Heights location, and Houston Methodist's Sugar Land and Willowbrook hospitals. The rankings also include specialty categories where the University of Texas MD Anderson Cancer Center once again ranked No. 1 in the nation for cancer treatment. What they're saying:"Houston's health care system is impressively represented in the 2025-2026 U.S. News Best Hospitals rankings, with 12 Best Regional Hospitals recognized in the Houston metro," Chelsey Wen, senior health data analyst at U.S. News, tells Axios. "This broad recognition … assures residents of widespread access to high-quality patient care," Wen says. Here are the top-ranked hospitals in Houston:
